# Recombinant Human Erythropoietin

## EPO inj 1 IU (H/D OPD Only)

| TAH Drug Code      | [IEPO1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IEPO1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of anemia associated with chronic renal failure in pediatric & adult patients on hemodialysis & adult patients on peritoneal dialysis. Treatment of severe anemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Treatment of anaemia in adult cancer patients receiving chemotherapy & to maintain Hb levels in adult cancer patients at risk of developing anemia during chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Dosing             | Chronic renal failure Adult patients Correction phase: 50 IU/kg 3 times/week IV. When necessary, dose adjustments should be made in increments of 25 IU/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (10-12 g/dL ) is achieved. Maintenance phase: Individualised dose. The recommended total weekly dose is 75-300 IU/kg. Pediatric patients Correction phase: 50 IU/kg 3 times/week IV. When necessary, dose adjustments should be made in increments of 25 IU/kg 3 times/week at intervals of at least 4 weeks until the target Hb concentration (9.5-11 g/dL) is achieved. Maintenance phase: Generally, children < 30 kg require higher maintenance doses than children > 30 kg & adults Cancer patients Initially 150 IU/kg 3 times/week. If after 4 weeks the Hb increase is < 1 g/dL the dose should be increased to 300 IU/kg for an additional 4 weeks. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Contraindications  | Patients who develop antibody-mediated Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin should not receive Eprex or any other erythropoietin . Uncontrolled hypertension. Known hypersensitivity to any of the components of Eprex.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Increased BP, thrombotic or vascular events. Flu-like symptoms, bone pain & chills after inj. Seizures. Skin reactions, palpebral edema. Rarely, erythroblastopenia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Pregnancy          | Compatible â€“ Maternal Benefit >> Embryo-Fetal Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/recombinant-human-erythropoietin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

